Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease-Reference-Cited by-同舟云学术

Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease

Published:2022-09-10 Issue:2 Volume:19 Page:708-720
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Jutten Roos J.¹^ORCID,Papp Kathryn V.¹²,Hendrix Suzanne³,Ellison Noel³,Langbaum Jessica B.⁴,Donohue Michael C.⁵,Hassenstab Jason⁶,Maruff Paul⁷⁸,Rentz Dorene M.¹²,Harrison John⁹¹⁰¹¹,Cummings Jeffrey¹²,Scheltens Philip¹¹,Sikkes Sietske A. M.¹¹¹³

Affiliation:

1. Department of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA

2. Department of Neurology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA

3. Pentara Corporation Salt Lake City Utah USA

4. Banner Alzheimer's Institute Phoenix Arizona USA

5. Alzheimer's Therapeutic Research Institute Keck School of Medicine University of Southern California San Diego California USA

6. Knight Alzheimer Disease Research Center Department of Neurology Washington University in St. Louis St. Louis Missouri USA

7. Cogstate Ltd. Melbourne Victoria Australia

8. The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia

9. Metis Cognition Ltd. Kilmington UK

10. Department of Psychiatry Psychology & Neuroscience King's College London UK

11. Alzheimer Center Amsterdam Department of Neurology Amsterdam UMC, location VUmc VU University Amsterdam The Netherlands

12. Chambers‐Grundy Center for Transformative Neuroscience Department of Brain Health School of Integrated Health Sciences University of Nevada Las Vegas (UNLV) Las Vegas Nevada USA

13. Department of Clinical Neuro and Developmental Psychology Faculty of Movement and Behavioral Sciences VU University Amsterdam The Netherlands

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12773

Reference108 articles.

1. The “rights” of precision drug development for Alzheimer’s disease

2. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review

3. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” – a practical guideline

4. FDA Early Alzheimer's Disease: Developing Drugs for Treatment. Guidance for Industry.2018.

5. A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cognivue Clarity ® Characterizes Mild Cognitive Impairment and Alzheimer’s Disease in Biomarker Confirmed Cohorts in the Bio-Hermes Study;2024-09-10

2. Enlarged perivascular space burden predicts declines in cognitive and functional performance;Journal of the Neurological Sciences;2024-09

3. Cognitive Assessment with Cognivue Clarity®: Psychometric Properties and Normative Ranges in a Diverse Population;Journal of Alzheimer's Disease;2024-07-16

4. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration;BMJ;2024-07-09

5. The effect of years of schooling and age on CERAD‐MX performance in Mexican preclinical carriers of the APP_V717I mutation: Randomized data simulation;Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring;2024-07